StockWatch
·
Pharmaceuticals
Quarterly Updates14 Nov 2026, 04:42 pm

Orchid Pharma: QIP Fund Use Deviation for Sept 30, 2026 Quarter

AI Summary

Orchid Pharma Limited has filed a Statement of Deviation or Variation for the quarter ended September 30, 2026, regarding the use of proceeds from its Qualified Institutional Placement (QIP). The company reported a deviation in the allocation of QIP funds. The project for a new block at the API Facility in Alathur has been postponed. Consequently, funds originally allocated for this project have been reallocated with shareholder approval obtained at the AGM on September 30, 2025. The reallocation aims to mitigate financial burdens, improve profits, and ensure optimal utilization of QIP proceeds. The original objects included investment in a subsidiary for a Jammu manufacturing facility, repayment of borrowings, capital expenditure for the Alathur API facility, and general corporate purposes. The deviation primarily impacts the Alathur API facility allocation, with funds being reallocated to other purposes, including general corporate purposes, which saw a revision due to net proceeds transferred to the monitoring account being higher than initially proposed.

Key Highlights

  • Orchid Pharma reports deviation in QIP fund utilization for Q2 FY27.
  • Postponement of Alathur API facility project led to fund reallocation.
  • Shareholder approval secured for modified fund allocation.
  • Reallocation aims to improve profitability and resource utilization.
  • Deviation primarily affects capital expenditure for the Alathur facility.